A PILOT-STUDY OF CLONIDINE PLUS PHYSOSTIGMINE IN ALZHEIMERS-DISEASE

被引:13
作者
BIERER, LM [1 ]
AISEN, PS [1 ]
DAVIDSON, M [1 ]
RYAN, TM [1 ]
SCHMEIDLER, J [1 ]
DAVIS, KL [1 ]
机构
[1] CUNY MT SINAI SCH MED,DEPT PSYCHIAT,NEW YORK,NY 10029
来源
DEMENTIA | 1994年 / 5卷 / 05期
关键词
ALZHEIMERS DISEASE; CLONIDINE; PHYSOSTIGMINE;
D O I
10.1159/000106731
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
To assess the feasibility of one approach to combined cholinergic/noradrenergic treatment in Alzheimer's disease, ten patients were enrolled in a 2-week placebo-controlled study of oral physostigmine plus clonidine. The Alzheimer's Disease Assessment Scale (ADAS) was used as the primary outcome measure. Neither physostigmine alone, nor the combination of physostigmine plus clonidine, was associated with a statistically significant improvement for the group. Three patients did show an improvement of at least 4 points on the total ADAS score with the drug combination. The implications of these results for treatment strategies are discussed.
引用
收藏
页码:243 / 246
页数:4
相关论文
共 23 条